AYTU BIOPHARMA, INC Revenue Disclosure
Note 3 - Revenue
The Company disaggregates its net revenue from continuing operations by product portfolio, which for the years ended June 30, 2025, and 2024, includes the ADHD Portfolio, comprised primarily of Adzenys and Cotempla; and the Pediatric Portfolio, comprised primarily of Karbinal, Poly-Vi-Flor and Tri-Vi-Flor. The Company’s disaggregation of revenue is consistent with its operating segment.
Net Revenue by Product Portfolio
Net revenue disaggregated by product portfolios for the years ended June 30, 2025, and 2024, were as follows:
| Year Ended | ||||||||
| June 30, | ||||||||
| 2025 | 2024 | |||||||
| (in thousands) | ||||||||
| ADHD Portfolio | $ | 57,576 | $ | 57,784 | ||||
| Pediatric Portfolio | 8,769 | 7,280 | ||||||
| Other | 37 | 119 | ||||||
| Total net revenue | $ | 66,382 | $ | 65,183 | ||||
Other includes net revenue from various discontinued or deprioritized products. The Consumer Health business was divested in the first quarter of fiscal 2025 and is reported within discontinued operations (see Note 20 - Discontinued Operations).
Net Revenue by Geographic Location
The Company’s net revenue is predominately within the United States, with insignificant international sales.
Want the next AYTU BIOPHARMA, INC revenue disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment AYTU BIOPHARMA, INC's next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Sep 23, 2025 | Showing above |
| 2024 | Sep 26, 2024 | |
| 2023 | Oct 12, 2023 | |
| 2022 | Sep 27, 2022 | |
| 2021 | Sep 28, 2021 | |
| 2020 | Oct 6, 2020 | |
| 2019 | Sep 26, 2019 | |
| 2017 | Aug 31, 2017 | |
| 2016 | Sep 1, 2016 | |
| 2015 | Sep 28, 2015 | |
About Revenue Disclosures
Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.
Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.